AJHE2317 - CME/CMLE - Helicobacter pylori–negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach-Helicobacter pylori–negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach

Helicobacter pylori–negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach

Pdf Summary

The document discusses the increasing incidence of HP-negative mucosa-associated lymphoid tissue (MALT) lymphomas, a subgroup associated with challenges in diagnosis and management. The study indicates unique clinicopathologic features of HP-negative MALT lymphomas, showing a generally favorable prognosis. The research involved reviewing cases of primary gastric MALT lymphomas from 2000 to 2017, categorizing them based on HP status and gastritis, and analyzing their clinical data and outcomes. It was found that HP-negative cases, particularly those without gastritis, often presented with mass lesions, had a varied response to treatments like antibiotics, radiation, rituximab, or chemotherapy, and showed recurrence rates similar to HP-positive cases. The study also touches on the impact of t(11;18)(q21;q21) translocation in HP-negative cases and the role of antibiotic therapy for these lymphomas. Overall, the findings suggest that HP-negative MALT lymphomas without evident gastritis represent a unique subgroup with good prognosis despite varied management approaches and require further study for a deeper understanding of their pathophysiology and optimal treatment strategies. The study highlights the changing trends in gastric MALT lymphomas, emphasizing the importance of recognizing and managing HP-negative cases effectively.

Keywords

HP-negative MALT lymphomas

gastric MALT lymphomas

clinicopathologic features

HP status

gastritis

treatment response

recurrence rates

t(11;18)(q21;q21) translocation

antibiotic therapy

optimal treatment strategies